Hsuan-Shu Lee

Hsuan-Shu Lee

Auto-generated profile, based on publicly available information

Hsuan-Shu Lee

Institute of Biotechnology, National Taiwan University, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2012 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
MLMei-Hsuan Lee
Mei-Hsuan Lee
HYHwai-I. Yang
Hwai-I. Yang
SLSheng-Nan Lu
Sheng-Nan Lu
CJChin-Lan Jen
Chin-Lan Jen
SYSan-Lin You
San-Lin You
FGfor the R.E.V.E.A.L.-HCV Study Group
for the R.E.V.E.A.L.-HCV Study Group
Background. The study aimed to evaluate the risk of hepatitis C virus (HCV) infection on hepatic and extrahepatic deaths. Methods. A cohort of 23 820 adults aged 30–65 years old were enrolled during 1991–1992. The seromarkers hepatitis B surface antigen (HBsAg), anti-HCV, and serum HCV RNA levels at study entry were tested. The vital status was ascertained through computerized linkage with national death certification profiles from 1991 to 2008. Results. There were 19 636 HBsAg-seronegatives, including 18 541 anti-HCV seronegatives and 1095 anti-HCV seropositives. Among anti-HCV seropositives, 69.4% had detectable serum HCV RNA levels. There were 2394 deaths that occurred during an average follow-up period of 16.2 years. Compared with anti-HCV seronegatives, anti-HCV seropositives had higher mortality from both hepatic and extrahepatic diseases, showing multivariate-adjusted hazard ratio (95% confidence interval) of 1.89 (1.66–2.15) for all causes of death; 12.48 (9.34–16.66) for hepatic diseases; 1.35 (1.15–1.57) for extrahepatic diseases; 1.50 (1.10–2.03) for circulatory diseases; 2.77 (1.49–5.15) for nephritis, nephrotic syndrome, and nephrosis; 4.08 (1.38–12.08) for esophageal cancer; 4.19 (1.18–14.94) for prostate cancer; and 8.22 (1.36–49.66) for thyroid cancer. Anti-HCV seropositives with detectable HCV RNA levels had significantly higher mortality from hepatic and extrahepatic diseases than anti-HCV seropositives with undetectable HCV RNA. Conclusions. Monitoring HCV RNA in anti-HCV seropositives is essential for the prediction of mortality associated with hepatitis C.

1 January 2007 in Journal of the Formosan Medical Association
Verified
Journal Article
Closed access
CCChien-Hung Chen
Chien-Hung Chen
PYPei-Ming Yang
Pei-Ming Yang
GHGuan-Tarn Huang
Guan-Tarn Huang
HLHsuan-Shu Lee
Hsuan-Shu Lee
JSJuei-Low Sung
Juei-Low Sung
JSJin-Chuan Sheu
Jin-Chuan Sheu

13 November 2013 in Gut
Verified
Journal Article
Closed access
PDF file
JLJessica Liu
Jessica Liu
HYHwai-I Yang
Hwai-I Yang
MLMei-Hsuan Lee
Mei-Hsuan Lee
SLSheng-Nan Lu
Sheng-Nan Lu
CJChin-Lan Jen
Chin-Lan Jen
CCChien-Jen Chen
Chien-Jen Chen
Background and aims The associations between long-term risk of hepatocellular carcinoma (HCC) and spontaneous seroclearance of HBV e antigen (HBeAg), HBV DNA and HBV surface antigen (HBsAg) have never been examined by a prospective study using serially measured seromarkers. This study aimed to assess the importance of spontaneous HBeAg, HBV DNA and HBsAg seroclearance in the prediction of HCC risk. Methods This study included 2946 HBsAg seropositive individuals who were seronegative for antibodies against HCV and free of liver cirrhosis. Serial serum samples collected at study entry and follow-up health examinations were tested for HBeAg, HBV DNA and HBsAg. Cox proportional hazards models were used to calculate the HRs of developing HCC after seroclearance of HBV markers. Results The HR (95% CI) of developing HCC after seroclearance of HBeAg, HBV DNA and HBsAg during follow-up was 0.63 (0.38 to 1.05), 0.24 (0.11 to 0.57) and 0.18 (0.09 to 0.38), respectively, after adjustment for age, gender and serum level of alanine aminotransferase at study entry. High HBV DNA levels at the seroclearance of HBeAg (mean±SD, 4.35±1.64 log10 IU/mL) may explain the non-significant association between HBeAg seroclearance and HCC risk. Among HBeAg seronegative participants with detectable serum HBV DNA at study entry, the lifetime (30–75-years-old) cumulative incidence of HCC was 4.0%, 6.6% and 14.2%, respectively, for those with seroclearance of both HBV DNA and HBsAg, seroclearance of HBV DNA only, and seroclearance of neither. Conclusions Spontaneous seroclearance of HBV DNA and HBsAg are important predictors of reduced HCC risk.

12 November 2008 in Journal of Tissue Engineering and Regenerative Medicine
Verified
Journal Article
Closed access
PDF file
WLWan-Ju Li
Wan-Ju Li
HCHongsen Chiang
Hongsen Chiang
TKTzong-Fu Kuo
Tzong-Fu Kuo
HLHsuan-Shu Lee
Hsuan-Shu Lee
CJChing-Chuan Jiang
Ching-Chuan Jiang
RTRocky S. Tuan
Rocky S. Tuan
The aim of this study was to evaluate a cell‐seeded nanofibrous scaffold for cartilage repair in vivo. We used a biodegradable poly(ε‐caprolactone) (PCL) nanofibrous scaffold seeded with allogeneic chondrocytes or xenogeneic human mesenchymal stem cells (MSCs), or acellular PCL scaffolds, with no implant as a control to repair iatrogenic, 7 mm full‐thickness cartilage defects in a swine model. Six months after implantation, MSC‐seeded constructs showed the most complete repair in the defects compared to other groups. Macroscopically, the MSC‐seeded constructs regenerated hyaline cartilage‐like tissue and restored a smooth cartilage surface, while the chondrocyte‐seeded constructs produced mostly fibrocartilage‐like tissue with a discontinuous superficial cartilage contour. Incomplete repair containing fibrocartilage or fibrous tissue was found in the acellular constructs and the no‐implant control group. Quantitative histological evaluation showed overall higher scores for the chondrocyte‐ and MSC‐seeded constructs than the acellular construct and the no‐implant groups. Mechanical testing showed the highest equilibrium compressive stress of 1.5 MPa in the regenerated cartilage produced by the MSC‐seeded constructs, compared to 1.2 MPa in the chondrocyte‐seeded constructs, 1.0 MPa in the acellular constructs and 0.2 MPa in the no‐implant group. No evidence of immune reaction to the allogeneically‐ and xenogeneically‐derived regenerated cartilage was observed, possibly related to the immunosuppressive activities of MSCs, suggesting the feasibility of allogeneic or xenogeneic transplantation of MSCs for cell‐based therapy. Taken together, our results showed that biodegradable nanofibrous scaffolds seeded with MSCs effectively repair cartilage defects in vivo, and that the current approach is promising for cartilage repair. Copyright © 2008 John Wiley & Sons, Ltd.

1 September 1996 in Journal of Hepatology
Verified
Journal Article
Closed access
GHGuan-Tarn Huang
Guan-Tarn Huang
JSJin-Chuan Sheu
Jin-Chuan Sheu
PYPei-Ming Yang
Pei-Ming Yang
HLHsuan-Shu Lee
Hsuan-Shu Lee
TWTeh-Hong Wang
Teh-Hong Wang
DCDing-Shinn Chen
Ding-Shinn Chen

1 March 2003 in Stem Cells
Verified
Journal Article
Open access
PDF file
HLHsuan‐Shu Lee
Hsuan‐Shu Lee
GHGuan‐Tarn Huang
Guan‐Tarn Huang
HCHongsen Chiang
Hongsen Chiang
LCLing‐Ling Chiou
Ling‐Ling Chiou
MCMin-Huey Chen
Min-Huey Chen
CJChing-Chuan Jiang
Ching-Chuan Jiang
STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. STEM CELLS is read and written by clinical and basic scientists whose expertise encompasses the rapidly expanding fields of stem and progenitor cell biology. STEM CELLS welcomes original articles and concise reviews describing basic laboratory investigations of stem cells and the translation of their clinical aspects of characterization and manipulation from the bench to patient care. The journal covers all aspects of stem cells embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; stem cell technology: epigenetics, genomics, proteomics, and metabonomics; cancer stem cells; translational and clinical research; and regenerative medicine.